104 related articles for article (PubMed ID: 18351636)
1. Cospray-dried unfractionated heparin with L-leucine as a dry powder inhaler mucolytic for cystic fibrosis therapy.
Shur J; Nevell TG; Ewen RJ; Price R; Smith A; Barbu E; Conway JH; Carroll MP; Shute JK; Smith JR
J Pharm Sci; 2008 Nov; 97(11):4857-68. PubMed ID: 18351636
[TBL] [Abstract][Full Text] [Related]
2. Inhaled mucoactive particles with tailored architecture for enhanced aerodynamicity, stability and efficacy.
Lee SH; Heng D; Teo JWP; Toh FKY; Tan RBH
Int J Pharm; 2019 Dec; 572():118740. PubMed ID: 31648015
[TBL] [Abstract][Full Text] [Related]
3. The spray drying of unfractionated heparin: optimization of the operating parameters.
Shur J; Nevell TG; Shute JK; Smith JR
Drug Dev Ind Pharm; 2008 Jun; 34(6):559-68. PubMed ID: 18568905
[TBL] [Abstract][Full Text] [Related]
4. The influence of formulation components on the aerosolisation properties of spray-dried powders.
Rabbani NR; Seville PC
J Control Release; 2005 Dec; 110(1):130-40. PubMed ID: 16226334
[TBL] [Abstract][Full Text] [Related]
5. Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients.
Akdag Cayli Y; Sahin S; Buttini F; Balducci AG; Montanari S; Vural I; Oner L
Drug Dev Ind Pharm; 2017 Aug; 43(8):1378-1389. PubMed ID: 28420285
[TBL] [Abstract][Full Text] [Related]
6. Cospray dried antibiotics for dry powder lung delivery.
Adi H; Young PM; Chan HK; Stewart P; Agus H; Traini D
J Pharm Sci; 2008 Aug; 97(8):3356-66. PubMed ID: 17990305
[TBL] [Abstract][Full Text] [Related]
7. Budesonide dry powder for inhalation: effects of leucine and mannitol on the efficiency of delivery.
Rattanupatam T; Srichana T
Drug Deliv; 2014 Sep; 21(6):397-405. PubMed ID: 24401124
[TBL] [Abstract][Full Text] [Related]
8. The effect of vehicle on physical properties and aerosolisation behaviour of disodium cromoglycate microparticles spray dried alone or with L-leucine.
Najafabadi AR; Gilani K; Barghi M; Rafiee-Tehrani M
Int J Pharm; 2004 Nov; 285(1-2):97-108. PubMed ID: 15488683
[TBL] [Abstract][Full Text] [Related]
9. Development of inhalable formulations of anti-inflammatory drugs to potentially treat smoke inhalation injury in burn victims.
Thai A; Xiao J; Ammit AJ; Rohanizadeh R
Int J Pharm; 2010 Apr; 389(1-2):41-52. PubMed ID: 20080165
[TBL] [Abstract][Full Text] [Related]
10. Spray-Dried Influenza Antigen with Trehalose and Leucine Produces an Aerosolizable Powder Vaccine Formulation that Induces Strong Systemic and Mucosal Immunity after Pulmonary Administration.
Sou T; Morton DA; Williamson M; Meeusen EN; Kaminskas LM; McIntosh MP
J Aerosol Med Pulm Drug Deliv; 2015 Oct; 28(5):361-71. PubMed ID: 25714115
[TBL] [Abstract][Full Text] [Related]
11. The use of amino acids to enhance the aerosolisation of spray-dried powders for pulmonary gene therapy.
Li HY; Seville PC; Williamson IJ; Birchall JC
J Gene Med; 2005 Mar; 7(3):343-53. PubMed ID: 15515142
[TBL] [Abstract][Full Text] [Related]
12. Inhalable Spray-Freeze-Dried Powder with L-Leucine that Delivers Particles Independent of Inspiratory Flow Pattern and Inhalation Device.
Otake H; Okuda T; Hira D; Kojima H; Shimada Y; Okamoto H
Pharm Res; 2016 Apr; 33(4):922-31. PubMed ID: 26643921
[TBL] [Abstract][Full Text] [Related]
13. Optimization of a dry powder inhaler formulation of nacystelyn, a new mucoactive agent.
Vanderbist F; Wery B; Moyano-Pavon I; Moës AJ
J Pharm Pharmacol; 1999 Nov; 51(11):1229-34. PubMed ID: 10632079
[TBL] [Abstract][Full Text] [Related]
14. Unfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis.
Broughton-Head VJ; Shur J; Carroll MP; Smith JR; Shute JK
Am J Physiol Lung Cell Mol Physiol; 2007 Nov; 293(5):L1240-9. PubMed ID: 17827252
[TBL] [Abstract][Full Text] [Related]
15. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.
Adi H; Young PM; Chan HK; Agus H; Traini D
Eur J Pharm Sci; 2010 Jun; 40(3):239-47. PubMed ID: 20371286
[TBL] [Abstract][Full Text] [Related]
16. Clarithromycin and N-acetylcysteine co-spray-dried powders for pulmonary drug delivery: A focus on drug solubility.
Manniello MD; Del Gaudio P; Aquino RP; Russo P
Int J Pharm; 2017 Nov; 533(2):463-469. PubMed ID: 28377314
[TBL] [Abstract][Full Text] [Related]
17. Non-steroidal anti-inflammatory drug for pulmonary administration: design and investigation of ketoprofen lysinate fine dry powders.
Stigliani M; Aquino RP; Del Gaudio P; Mencherini T; Sansone F; Russo P
Int J Pharm; 2013 May; 448(1):198-204. PubMed ID: 23528281
[TBL] [Abstract][Full Text] [Related]
18. Leucine enhances aerosol performance of naringin dry powder and its activity on cystic fibrosis airway epithelial cells.
Prota L; Santoro A; Bifulco M; Aquino RP; Mencherini T; Russo P
Int J Pharm; 2011 Jun; 412(1-2):8-19. PubMed ID: 21459138
[TBL] [Abstract][Full Text] [Related]
19. The role of particle properties in pharmaceutical powder inhalation formulations.
Chew NY; Chan HK
J Aerosol Med; 2002; 15(3):325-30. PubMed ID: 12396421
[TBL] [Abstract][Full Text] [Related]
20. The Cyclops for pulmonary delivery of aminoglycosides; a new member of the Twincer™ family.
Hoppentocht M; Akkerman OW; Hagedoorn P; Frijlink HW; de Boer AH
Eur J Pharm Biopharm; 2015 Feb; 90():8-15. PubMed ID: 25615881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
